These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 19486171)

  • 1. Enhancement of haemostatic efficacy of plasma-derived FVIII by formulation with PEGylated liposomes.
    Dayan I; Robinson M; Baru M
    Haemophilia; 2009 Sep; 15(5):1006-13. PubMed ID: 19486171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancement of factor VIIa haemostatic efficacy by formulation with PEGylated liposomes.
    Yatuv R; Dayan I; Carmel-Goren L; Robinson M; Aviv I; Goldenberg-Furmanov M; Baru M
    Haemophilia; 2008 May; 14(3):476-83. PubMed ID: 18393980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factor VIII efficient and specific non-covalent binding to PEGylated liposomes enables prolongation of its circulation time and haemostatic efficacy.
    Baru M; Carmel-Goren L; Barenholz Y; Dayan I; Ostropolets S; Slepoy I; Gvirtzer N; Fukson V; Spira J
    Thromb Haemost; 2005 Jun; 93(6):1061-8. PubMed ID: 15968389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, pharmacokinetics and efficacy of factor VIIa formulated with PEGylated liposomes in haemophilia A patients with inhibitors to factor VIII--an open label, exploratory, cross-over, phase I/II study.
    Spira J; Plyushch O; Zozulya N; Yatuv R; Dayan I; Bleicher A; Robinson M; Baru M
    Haemophilia; 2010 Nov; 16(6):910-8. PubMed ID: 20491957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical evaluation of recombinant human factor VIII (BAY w 6240) in the treatment of hemophilia A.
    Fukui H; Yoshioka A; Shima M; Tanaka I; Koshihara K; Fukutake K; Fujimaki M
    Int J Hematol; 1991 Oct; 54(5):419-27. PubMed ID: 1756252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stability, efficacy, and safety of continuously infused sucrose-formulated recombinant factor VIII (rFVIII-FS) during surgery in patients with severe haemophilia.
    Martinowitz U; Luboshitz J; Bashari D; Ravid B; Gorina E; Regan L; Stass H; Lubetsky A
    Haemophilia; 2009 May; 15(3):676-85. PubMed ID: 19298381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Longer-acting factor VIII to overcome limitations in haemophilia management: the PEGylated liposomes formulation issue.
    Di Minno G; Cerbone AM; Coppola A; Cimino E; Di Capua M; Pamparana F; Tufano A; Di Minno MN
    Haemophilia; 2010 Jan; 16 Suppl 1():2-6. PubMed ID: 20059562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Binding of proteins to PEGylated liposomes and improvement of G-CSF efficacy in mobilization of hematopoietic stem cells.
    Yatuv R; Carmel-Goren L; Dayan I; Robinson M; Baru M
    J Control Release; 2009 Apr; 135(1):44-50. PubMed ID: 19135487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intranasal DDAVP induced increases in plasma von Willebrand factor alter the pharmacokinetics of high-purity factor VIII concentrates in severe haemophilia A patients.
    Deitcher SR; Tuller J; Johnson JA
    Haemophilia; 1999 Mar; 5(2):88-95. PubMed ID: 10215955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Timing and severity of inhibitor development in recombinant versus plasma-derived factor VIII concentrates: a SIPPET analysis.
    Peyvandi F; Cannavò A; Garagiola I; Palla R; Mannucci PM; Rosendaal FR;
    J Thromb Haemost; 2018 Jan; 16(1):39-43. PubMed ID: 29080391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prolonged bleeding-free period following prophylactic infusion of recombinant factor VIII reconstituted with pegylated liposomes.
    Spira J; Plyushch OP; Andreeva TA; Andreev Y
    Blood; 2006 Dec; 108(12):3668-73. PubMed ID: 16888098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancement of the efficacy of therapeutic proteins by formulation with PEGylated liposomes; a case of FVIII, FVIIa and G-CSF.
    Yatuv R; Robinson M; Dayan I; Baru M
    Expert Opin Drug Deliv; 2010 Feb; 7(2):187-201. PubMed ID: 20095942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the immunogenicity of different therapeutic preparations of human factor VIII in the murine model of hemophilia A.
    Delignat S; Dasgupta S; André S; Navarrete AM; Kaveri SV; Bayry J; André MH; Chtourou S; Tellier Z; Lacroix-Desmazes S
    Haematologica; 2007 Oct; 92(10):1423-6. PubMed ID: 18024377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of liposomal dose in recombinant factor VIII reconstituted with pegylated liposomes for the treatment of patients with severe haemophilia A.
    Spira J; Plyushch OP; Andreeva TA; Khametova RN
    Thromb Haemost; 2008 Sep; 100(3):429-34. PubMed ID: 18766258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The relevance of factor VIII (FVIII) pharmacokinetics to TDM and hemophilia a treatment: is B domain-deleted FVIII equivalent to full-length FVIII?
    Johnston A
    Ther Drug Monit; 2012 Feb; 34(1):110-7. PubMed ID: 22249347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical efficacy, safety and pharmacokinetic properties of the factor VIII concentrate Haemoctin SDH in previously treated patients with severe haemophilia A.
    Wolf DM; Rokicka-Milewska R; Lopaciuk S; Skotnicki AB; Klukowska A; Laguna P; Windyga J; Kotitschke R; Struff WG
    Haemophilia; 2004 Sep; 10(5):438-48. PubMed ID: 15357768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. A randomised cross-over, multi-centre study.
    Favaloro EJ; Lloyd J; Rowell J; Baker R; Rickard K; Kershaw G; Street A; Scarff K; Barrese G; Maher D; McLachlan AJ
    Thromb Haemost; 2007 Jun; 97(6):922-30. PubMed ID: 17549293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant, B-domain deleted factor VIII (r-VIII SQ): pharmacokinetics and initial safety aspects in hemophilia A patients.
    Fijnvandraat K; Berntorp E; ten Cate JW; Johnsson H; Peters M; Savidge G; Tengborn L; Spira J; Stahl C
    Thromb Haemost; 1997 Feb; 77(2):298-302. PubMed ID: 9157585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PEGylation of a factor VIII-phosphatidylinositol complex: pharmacokinetics and immunogenicity in hemophilia A mice.
    Peng A; Kosloski MP; Nakamura G; Ding H; Balu-Iyer SV
    AAPS J; 2012 Mar; 14(1):35-42. PubMed ID: 22173945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant and plasma-derived factor VIII products induce distinct splenic cytokine microenvironments in hemophilia A mice.
    Qadura M; Waters B; Burnett E; Chegeni R; Bradshaw S; Hough C; Othman M; Lillicrap D
    Blood; 2009 Jul; 114(4):871-80. PubMed ID: 19411636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.